SAN FRANCISCO, July 16, 2019 /PRNewswire/ -- Kindred
Biosciences, Inc. (NASDAQ: KIN), a commercial-stage
biopharmaceutical company focused on saving and improving the lives
of pets, will release its second quarter 2019 financial results on
August 1, 2019, after the market
close. The Company will host a conference call at 4:30 p.m. Eastern time/1:30 p.m. Pacific time that day.
Access the call by dialing toll-free (855) 433-0927 from the
U.S., or (484) 756-4262 internationally, and using conference ID
3784614.
The call will also be webcast live here, with a replay available
at that link for 30 days.
About Kindred Biosciences
Kindred Biosciences is a
commercial-stage biopharmaceutical company focused on saving and
improving the lives of pets. Its mission is to bring to pets the
same kinds of safe and effective medicines that human family
members enjoy. The company's strategy is to identify compounds and
targets that have already demonstrated safety and efficacy in
humans and to develop therapeutics based on these validated
compounds and targets for dogs, cats, and horses. KindredBio has a
deep pipeline of novel drugs and biologics in development across
many therapeutic classes. Its first approved drug is
Mirataz® (mirtazapine transdermal ointment) for the
management of weight loss in cats.
For more information, or to download the corporate presentation,
visit www.KindredBio.com/LearnMore. Stay connected with
KindredBio on Facebook at www.Facebook.com/KindredBio.
Important Safety Information
Mirataz®
(mirtazapine transdermal ointment) is for topical use in cats only
under veterinary supervision. Do not use in cats with a known
hypersensitivity to mirtazapine or any of the excipients or in cats
treated with monoamine oxidase inhibitors (MAOIs). Not for human
use. Keep out of reach of children. Wear gloves to apply and wash
hands after. Avoid contact with treated cat for 2 hours following
application. The most common adverse reactions include
application site reactions, behavioral abnormalities (vocalization
and hyperactivity), and vomiting. Please see the
full Prescribing Information.
Contacts
For investor inquiries:
Katja Buhrer
katja.buhrer@kindredbio.com
(917) 969-3438
View original content to download
multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-to-announce-second-quarter-2019-financial-results-300885126.html
SOURCE Kindred Biosciences, Inc.